{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:23:00Z","timestamp":1791958980860,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2016,11]]},"abstract":"Summary<\/jats:title>Posaconazole may be useful for salvage treatment (ST<\/jats:styled-content>) for invasive fungal infections (IFI<\/jats:styled-content>s). The aim of this study was to evaluate the efficacy of posaconazole ST<\/jats:styled-content> with either posaconazole oral suspension (SUS<\/jats:styled-content>) or delayed\u2010released tablet (TAB<\/jats:styled-content>) in patients with IFI<\/jats:styled-content>. A retrospective review of patients who received posaconazole ST<\/jats:styled-content> for IFI<\/jats:styled-content> at the University of Utah Health Sciences Center between December 2007 and March 2014 was conducted. A total of 14 episodes of posaconazole ST<\/jats:styled-content> for proven (9 episodes) and probable (5 episodes) IFI<\/jats:styled-content> were identified in 14 patients. The median age was 54 years and the majority of patients (64.3%) had underlying haematological diseases. Posaconazole SUS<\/jats:styled-content> and TAB<\/jats:styled-content> were used in 11 episodes and 3 episodes respectively. The duration of posaconazole ST<\/jats:styled-content> ranged from 28 to 370 days with a median of 65 days. Posaconazole ST<\/jats:styled-content> with TAB<\/jats:styled-content> achieved favourable serum posaconazole trough concentrations (median 1.4 \u03bcg mL\u22121<\/jats:sup>) compared to posaconazole SUS<\/jats:styled-content> (median 1.0 \u03bcg mL\u22121<\/jats:sup>). The overall clinical success rate with posaconazole ST<\/jats:styled-content> was 71.4% (10 of 14 episodes). One patient died of progression of IFI<\/jats:styled-content>. Adverse events were noted in two patients. Posaconazole SUS<\/jats:styled-content> or TAB<\/jats:styled-content> may be used effectively for IFI ST<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/myc.12524","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T08:46:54Z","timestamp":1468054014000},"page":"726-733","source":"Crossref","is-referenced-by-count":13,"title":["Utilization of posaconazole oral suspension or delayed\u2010released tablet salvage treatment for invasive fungal infection"],"prefix":"10.1111","volume":"59","author":[{"given":"Jong Hun","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases Department of Internal Medicine University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Benefield","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Utah Health Sciences Center Salt Lake City UT USA"},{"name":"Department of Pharmacotherapy College of Pharmacy University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali","family":"Ditolla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Utah Health Sciences Center Salt Lake City UT USA"},{"name":"Department of Pharmacotherapy College of Pharmacy University of Utah Salt Lake City UT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00208.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-014-9792-y"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12023"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.158"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181837585"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/508774"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01034-08"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.11.021"},{"key":"e_1_2_8_11_1","volume-title":"Noxafil (posaconazole) Prescribing Information","author":"Merck & Co., Inc","year":"2014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks268"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00222-12"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02448-13"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/590566"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/500212"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405065"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2013.54.5.1234"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.1.126-133.2006"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12600"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1086\/427752"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-12"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-13"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/504328"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1533"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0348-3"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04035-14"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01055.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01325-10"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fmyc.12524","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:18:47Z","timestamp":1696238327000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/myc.12524"],"URL":"https:\/\/doi.org\/10.1111\/myc.12524","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]}}}